Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hepatic Artery”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00096083
What this trial is testing

Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

Who this might be right for
Cancer
Delcath Systems Inc. 56
Testing effectiveness (Phase 2)UnknownNCT05877001
What this trial is testing

The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases

Who this might be right for
Colorectal Liver Metastases
Peking University Cancer Hospital & Institute 20
Testing effectiveness (Phase 2)Ended earlyNCT05220722
What this trial is testing

Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Who this might be right for
Hepatocellular CarcinomaIntrahepatic Cholangiocarcinoma
TriSalus Life Sciences, Inc. 23
Not applicableStudy completedNCT06774807
What this trial is testing

Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)

Who this might be right for
Healthy
University of Copenhagen 10
Early research (Phase 1)Study completedNCT00732836
What this trial is testing

Hepatic Arterial Infusion (HAI) of Abraxane

Who this might be right for
Liver CancerAdvanced CancersSolid Tumors
M.D. Anderson Cancer Center 64
Post-approval studies (Phase 4)Not Yet RecruitingNCT07790419
What this trial is testing

A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion

Who this might be right for
Liver Cancer
Zhai Wenlong 40
Testing effectiveness (Phase 2)Study completedNCT05532319
What this trial is testing

HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC

Who this might be right for
Liver Cancer
Guangxi Medical University 64
Not applicableStudy completedNCT04771988
What this trial is testing

Radioembolization for Hepatocellular Carcinoma With Portal Vein Tumoral Thrombosis

Who this might be right for
Hepatocellular Carcinoma
IRCCS Azienda Ospedaliero-Universitaria di Bologna 17
Testing effectiveness (Phase 2)UnknownNCT05821361
What this trial is testing

HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma

Who this might be right for
Unrescetable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 30
Not applicableUnknownNCT03191123
What this trial is testing

Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma With Solitary Huge Tumor

Who this might be right for
Carcinoma, HepatocellularSurvival Rate
Huazhong University of Science and Technology 100
Testing effectiveness (Phase 2)WithdrawnNCT00035919
What this trial is testing

Safety and Efficacy of Targeted Gene Transfer in Colorectal Cancer Metastatic to Liver

Who this might be right for
Colorectal Neoplasms
University of Southern California
Large-scale testing (Phase 3)Study completedNCT00324727
What this trial is testing

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Who this might be right for
Intraocular MelanomaMelanoma (Skin)Metastatic Cancer
Delcath Systems Inc. 93
Testing effectiveness (Phase 2)Looking for participantsNCT06737913
What this trial is testing

HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma

Who this might be right for
Advanced Hepatocellular Carcinoma (HCC)
Sun Yat-sen University 76
Testing effectiveness (Phase 2)Study completedNCT04044313
What this trial is testing

HAIC Plus Lenvatinib and Toripalimab for Advanced HCC

Who this might be right for
Hepatocellular Carcinoma
Shi Ming 36
Very early researchStudy completedNCT03888859
What this trial is testing

ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma

Who this might be right for
Hepatocellular CarcinomaLiver CancerLiver Neoplasms+1 more
First Affiliated Hospital Xi'an Jiaotong University 12
Testing effectiveness (Phase 2)Study completedNCT00006050
What this trial is testing

Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Who this might be right for
Colorectal CancerMetastatic Cancer
UNICANCER
Not applicableUnknownNCT06505486
What this trial is testing

GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC

Who this might be right for
Intrahepatic Cholangiocarcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 21
Not applicableStudy completedNCT04880421
What this trial is testing

Diagnostic Performance of Arterial Time for CT Assessment of Parietal Enhancement Defect for the Diagnosis of Ischemia in Mechanical Small Bowel Occlusions: a Comparative Study With Portal Time

Who this might be right for
Bowel Obstruction Small
Fondation Hôpital Saint-Joseph 158
Large-scale testing (Phase 3)UnknownNCT05866172
What this trial is testing

HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC

Who this might be right for
Hepatocellular Carcinoma
Sun Yat-sen University 264
Large-scale testing (Phase 3)UnknownNCT04667351
What this trial is testing

HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial

Who this might be right for
HepatoCellular Carcinoma
Sun Yat-sen University 400
Next Page